Cerevance has reported a positive Phase 3 trial for solengepras, with the once-daily oral GPR6 inhibitor significantly reducing daily OFF time in people with Parkinson’s disease who were already receiving levodopa and other background treatments. The 150 mg dose also increased ON time without troublesome dyskinesia and improved patients’ ability to perform everyday motor activities, giving Cerevance a late-stage dataset supporting a potentially first-in-class non-dopaminergic treatment. The company now plans to meet with the U.S. Food and Drug Administration to discuss a potential New Drug Application.
The result is notable because most therapies used to manage Parkinson’s motor fluctuations ultimately modify dopamine signaling, whereas solengepras targets GPR6 within the indirect pathway of the basal ganglia without directly interacting with dopamine receptors. The primary treatment effect was statistically significant but moderate in absolute terms, reducing OFF time by about 0.61 hours, or 37 minutes, more than placebo over 12 weeks. That magnitude should therefore be weighed alongside the drug’s secondary motor findings, non-motor signals and apparently differentiated tolerability profile rather than interpreted in isolation.
Phase 3 ARISE trial met its primary endpoint with benefit emerging by Week 2
ARISE was a randomized, double-blind, placebo-controlled Phase 3 study involving 341 adults with Parkinson’s disease who were experiencing motor fluctuations despite ongoing treatment. Participants entered the study with an average of 5.65 hours of OFF time per day and continued their usual Parkinson’s medications while receiving once-daily solengepras 75 mg, solengepras 150 mg or placebo for 12 weeks.
The prespecified primary endpoint compared the 150 mg dose with placebo on change in average daily OFF time. Patients receiving solengepras 150 mg experienced a 1.56-hour reduction from baseline compared with a 0.95-hour reduction among placebo recipients, producing a placebo-adjusted difference of 0.61 hours and a p-value of 0.0350.
Separation was apparent relatively early. At Week 2, the first post-baseline assessment, the difference versus placebo was 0.75 hours, with a nominal p-value of 0.0022, and Cerevance reported that the treatment advantage continued at subsequent visits through Week 12.
OFF time refers to periods when the effect of levodopa and other Parkinson’s medication wears off and motor symptoms such as slowness, stiffness or tremor re-emerge. Motor fluctuations frequently become increasingly difficult to manage as Parkinson’s progresses and patients become more dependent on externally administered dopamine replacement.
The absolute placebo-adjusted reduction of approximately 37 minutes is important when interpreting the result. A systematic review of established adjunctive drug classes reported average placebo-adjusted reductions in OFF time of roughly 0.8 hours with COMT inhibitors, 1.1 hours with dopamine agonists and 0.9 hours with MAO-B inhibitors, although differences in trial design and patient populations prevent reliable direct comparisons with ARISE.
Solengepras therefore should not yet be described as demonstrably more effective than existing adjunctive therapies. Its potential differentiation instead lies in achieving a meaningful reduction in OFF time through a different neural mechanism while potentially avoiding some adverse effects created by increasing dopaminergic stimulation.
More ON time and better daily motor function broaden the Phase 3 efficacy signal
The ARISE findings were not limited to the primary endpoint. Patients receiving solengepras 150 mg gained 1.58 hours of ON time without troublesome dyskinesia from baseline compared with a 0.98-hour increase with placebo, resulting in a statistically significant placebo-adjusted advantage of 0.60 hours.
That result is clinically relevant because simply reducing OFF time would be less useful if the recovered time were replaced by disabling involuntary movements. Dyskinesia is a common complication of long-term dopaminergic treatment and can become increasingly difficult to balance against the need for adequate motor control.
ARISE also showed improvement in the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale Part II, which evaluates motor experiences of daily living. Solengepras produced a placebo-adjusted improvement of 1.91 points, with a p-value of 0.0008. Patients receiving the 150 mg dose improved by 2.05 points from baseline compared with only 0.14 points in the placebo group.
This measure captures practical difficulties involving activities such as speech, eating, dressing, walking and other aspects of daily life. The result therefore provides additional evidence that the OFF-time reduction translated into patient-relevant functional improvement rather than appearing only in diary measurements.
The consistency across OFF time, ON time and daily motor function makes the Phase 3 result more persuasive than the primary endpoint alone. However, Cerevance has released topline findings rather than a complete peer-reviewed analysis, so additional data will be important for understanding subgroup consistency, dose response and the full statistical hierarchy of secondary outcomes.
Daytime sleepiness and quality-of-life findings suggest a broader non-motor effect
Parkinson’s disease also produces substantial non-motor symptoms, including sleep disturbance, daytime somnolence, cognitive changes, mood symptoms and apathy. These problems can contribute heavily to disability even when motor symptoms are reasonably controlled. On the Epworth Sleepiness Scale, solengepras 150 mg improved daytime sleepiness by 1.39 points from baseline compared with 0.41 points for placebo, producing a placebo-adjusted difference of 0.98 points with a nominal p-value of 0.009.
Quality of life measured with the Parkinson’s Disease Questionnaire-39 also improved. The placebo-adjusted difference was 2.87 points in favor of solengepras, with a nominal p-value of 0.012. The PDQ-39 examines areas including mobility, emotional well-being, communication and social relationships.
These findings are supportive rather than equivalent to the statistically controlled primary endpoint. Cerevance identified the quality-of-life analysis as exploratory, while the reported p-values for some non-motor measures were nominal, meaning they were not necessarily protected against the increased risk of chance findings created by multiple comparisons.
Still, the pattern is scientifically relevant because solengepras was designed to regulate a disease-relevant basal ganglia circuit rather than simply increase dopamine availability. Earlier studies had also produced signals involving sleep and non-motor function, giving some consistency to the hypothesis that GPR6 inhibition could affect a broader range of Parkinson’s symptoms.
GPR6 inhibition offers a different strategy from increasing dopamine signaling
Levodopa remains the cornerstone of Parkinson’s treatment because it replaces dopamine lost as dopaminergic neurons degenerate. Over time, however, shorter and less predictable responses can result in repeated OFF episodes, while increasing dopaminergic stimulation can contribute to dyskinesia, hallucinations, somnolence and other treatment complications.
Solengepras, previously known as CVN424, instead inhibits GPR6. Cerevance identified the receptor using its NETSseq platform and found that GPR6 is strongly expressed in D2-positive medium spiny neurons of the basal ganglia indirect pathway, while expression is much lower in D1-positive neurons associated with the direct pathway.
The indirect pathway acts broadly as a brake on movement, while the direct pathway facilitates movement. Parkinson’s disease disrupts the balance between these circuits as dopamine declines. Cerevance’s strategy is to reduce excessive indirect-pathway activity through GPR6 inhibition without directly increasing dopamine or stimulating dopamine receptors.
The concept had already produced encouraging Phase 2 adjunctive data. In an earlier study, solengepras 150 mg reduced average daily OFF time by approximately 1.3 hours versus placebo after 27 days, providing the signal that supported progression into ARISE.
Results in untreated early Parkinson’s disease have been less definitive. The Phase 2 ASCEND monotherapy trial showed only a small, non-statistically significant improvement on its combined motor endpoint, although functional and non-motor measures generated supportive signals. Those findings suggest the clearest current development case for solengepras is as an adjunct to existing therapy in patients experiencing motor fluctuations.
Safety profile could become an important differentiator if confirmed over longer treatment
Solengepras was generally well tolerated during the 12-week ARISE study. Ninety-one percent of randomized participants completed treatment, while discontinuations because of adverse events occurred in 3.5% of patients in each treatment group, including placebo. No serious adverse events were reported among patients receiving solengepras 150 mg, compared with serious events in 1.8% of the 75 mg group and 0.9% of placebo recipients. Dyskinesia occurred in 4.4% of patients receiving the 150 mg dose compared with 1.8% on placebo.
The most frequently reported adverse events with solengepras 150 mg were headache and urinary tract infection, each occurring in 8.0% of patients. Insomnia and nausea were each reported in 6.2%, compared with 0.9% and 1.8%, respectively, among placebo recipients.
Cerevance characterized the relative scarcity of conventional dopaminergic adverse effects as consistent with solengepras’ mechanism. That possibility is important but should not be interpreted as proof of superior tolerability versus approved adjunctive therapies because ARISE used placebo rather than an active comparator. Longer-term exposure will also be necessary. Parkinson’s treatment is chronic, and a 12-week controlled study cannot fully characterize adverse effects that may emerge with months or years of GPR6 inhibition.
FDA discussions will determine whether ARISE provides enough evidence for an NDA
Cerevance said it plans to meet with the FDA to discuss the regulatory path for solengepras and a potential New Drug Application. The company has not yet announced that it will file an NDA or whether regulators will consider the existing Phase 2 and Phase 3 package sufficient without another pivotal trial.
ARISE provides a conventionally positive Phase 3 result on its primary endpoint, supported by statistically significant findings involving ON time and motor experiences of daily living. The overall efficacy difference is not unusually large compared with historical adjunctive Parkinson’s therapies, but the non-dopaminergic mechanism could give solengepras a distinct treatment role if its efficacy and tolerability are confirmed.
Cerevance is privately held and recently completed a $20 million Series C financing that extended its expected cash runway into mid-2027, beyond the Phase 3 readout. The company will now need sufficient resources either independently or through additional financing or partnership activity to carry solengepras through regulatory review and potential commercialization.
The larger clinical question is whether targeting GPR6 can provide sustained control of motor fluctuations without simply adding more dopaminergic stimulation to increasingly complex Parkinson’s regimens. ARISE provides the strongest evidence so far that the approach can work, but the forthcoming FDA discussions, complete Phase 3 dataset and longer-term safety evidence will determine whether solengepras can move from a novel mechanism to a new therapeutic class.
